OR Royalties (OR) to Release Earnings on Wednesday

OR Royalties (NYSE:OR) is expected to issue its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of $0.31 per share and revenue of $97.9330 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 10:00 AM ET.

OR Royalties (NYSE:OR) last issued its quarterly earnings data on Wednesday, May 6th. The basic materials company reported $0.40 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.06. The business had revenue of $102.83 million for the quarter, compared to analyst estimates of $103.27 million. OR Royalties had a return on equity of 15.10% and a net margin of 78.09%. On average, analysts expect OR Royalties to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

OR Royalties Trading Down 0.1%

Shares of OR Royalties stock opened at $29.74 on Monday. OR Royalties has a 1 year low of $27.54 and a 1 year high of $48.06. The company has a market cap of $5.57 billion, a price-to-earnings ratio of 22.19 and a beta of 0.75. The company’s fifty day simple moving average is $32.15 and its 200-day simple moving average is $37.56.

OR Royalties Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, July 15th. Stockholders of record on Tuesday, June 30th were issued a dividend of $0.065 per share. This represents a $0.26 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend was Tuesday, June 30th. This is a boost from OR Royalties’s previous quarterly dividend of $0.06. OR Royalties’s payout ratio is 18.66%.

Hedge Funds Weigh In On OR Royalties

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. FIL Ltd bought a new stake in OR Royalties during the fourth quarter worth about $29,000. Wells Fargo & Company MN raised its stake in shares of OR Royalties by 6.2% in the fourth quarter. Wells Fargo & Company MN now owns 5,901 shares of the basic materials company’s stock valued at $209,000 after acquiring an additional 346 shares during the last quarter. Merit Financial Group LLC bought a new position in shares of OR Royalties in the third quarter valued at approximately $215,000. Flow Traders U.S. LLC acquired a new position in shares of OR Royalties in the 3rd quarter worth approximately $217,000. Finally, Moors & Cabot Inc. acquired a new position in shares of OR Royalties in the 3rd quarter worth approximately $220,000. 68.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on OR shares. Wall Street Zen lowered shares of OR Royalties from a “buy” rating to a “hold” rating in a report on Saturday, June 6th. Zacks Research cut shares of OR Royalties from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Jefferies Financial Group dropped their price target on shares of OR Royalties from $40.00 to $34.00 and set a “hold” rating for the company in a research report on Monday, July 6th. Scotiabank cut their price target on shares of OR Royalties from $51.00 to $42.00 and set a “sector perform” rating for the company in a research note on Tuesday, July 14th. Finally, Royal Bank Of Canada decreased their price objective on OR Royalties from $50.00 to $45.00 and set an “outperform” rating on the stock in a report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, OR Royalties has an average rating of “Hold” and a consensus target price of $40.50.

About OR Royalties

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.